NZ542402A

NZ542402A - Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof

Info

Publication number: NZ542402A
Application number: NZ542402A
Authority: NZ
Inventors: Frank Himmelsbach; Flavio Solca
Original assignee: Boehringer Ingelheim Int
Priority date: 2003-02-20
Filing date: 2004-02-14
Publication date: 2008-09-26
Also published as: JP4468305B2; MXPA05008780A; EP1597240B1; CL2004000284A1; KR20050103230A; WO2004074263A1; ATE407929T1; DE502004008024D1; AU2004213129A1; BRPI0407709A; PE20040953A1; ZA200506121B; DE10307165A1; EP1597240A1; RU2005128826A; UY28191A1; TW200505912A; CA2516426A1; JP2006515005A; AR043249A1

Abstract

Bicyclic heterocycles of general formula (I) are disclosed, wherein Ra, Rb, Rc, Rd, Re, and X have the definitions indicated in the specification, the tautomers, stereoisomers, mixtures, and salts thereof, especially the physiologically acceptable salts thereof containing inorganic or organic acids having valuable pharmaceutical properties, especially an inhibiting effect on signal transduction mediated by tyrosine kinases, The disclosure also relates to the use of these compounds for treating diseases, especially cancer diseases and benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the production of these compounds and pharmaceutical compositions thereof.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 542402 WO 2004/074263 PCT/EP2004/001398 5* 24 02 82982pct Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof 5 The present invention relates to bicyclic heterocycles of general formula the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or 10 organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases and benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the preparation thereof. 15 In the above general formula I Ra denotes a hydrogen atom or a Ci-4-alkyl group, 20 Rb denotes a phenyl, benzyl or 1-phenylethyl group, wherein the phenyl nucleus in each case is substituted by the groups R1 to R3, while (MJ o (I). R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom, 25 a Ci-4-alkyl, hydroxy, Ci-4-alkoxy, C2-3-alkenyl or C2-3-alkynyl group, an aryl, aryloxy, arylmethyl or arylmethoxy group, INTELLECTUAL PROPERTY 0WQ1 OF NI 1 § SEP 2005 Received 2 a heteroaryl, heteroaryloxy, heteroarylmethyl or heteroarylmethoxy group, a methyl or methoxy group substituted by 1 to 3 fluorine atoms or 5 a cyano, nitro or amino group, and R3 denotes a hydrogen, fluorine, chlorine or bromine atom, 10 a methyl or trifluoromethyl group, Rc denotes a hydrogen atom or a fluorine, chlorine or bromine atom, a hydroxy or Ci-4-alkyioxy group, 15 a methoxy group substituted by 1 to 3 fluorine atoms, an ethyloxy group substituted by 1 to 5 fluorine atoms, 20 a C2-4-alkyloxy group which is substituted by a group R4, while R4 denotes a hydroxy, Ct-3-alkyloxy, C3-6-cycloalkyloxy, C3-6-cycloalkyl-Ci-3-alkyloxy, amino, Ci-3-alkylamino, di-(Ci-3-alkyl)amino, bis-(2-Ci-3-alkyloxy-ethyl)-amino, bis-(3-Ci-3-alkyloxy-propyl)-amino, pyrrolidin-1 -yl, 25 piperidin-1-yl, homopiperidin-1-yl, morpholin-4-yl, homomorpholin-4-yl, piperazin-1-yl, 4-(Ci-3-alkyl)-piperazin-1-yl, homopiperazin-1-yl or 4-(Ci-3-alkyl)-homopiperazin-1-yl group, a C3-7-cycloalkyloxy or C3-7-cycloalkyl-Ci-4-alkyloxy group, 30 a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy or tetrahydropyran-4-yloxy group, a tetrahydrofuranyl-Ci-4-alkyloxy or tetrahydropyranyl-Ci -4-alkyloxy group, 3 a pyrrolidin-3-yloxy, piperidin-3-yloxy or piperidin-4-yloxy group, a 1-(Ci-3-alkyl)-pyrrolidin-3-ytoxy, 1 -(Ci-3-afkyl)-piperidin-3-yloxy or 1-5 (Ci-3-alkyl)-piperidin-4-yloxy group, a Ci-4-alkoxy group which is substituted by a pyrrolidinyl, piperidinyl or homopiperidiriy! group substituted in the 1 position by the group R5, where 10 R5 denotes a hydrogen atom or a Ci-3-alkyl group, or a Ci-4-alkoxy group which is substituted by a morpholinyl or homomorpholinyl group substituted in the 4 position by the group R5, where R5 is as hereinbefore defined, 15 Re and Rd, which may be identical or different, in each case denote a hydrogen atom or a Ci-3-alkyl group and 20 X denotes a methyne group substituted by a cyano group or a nitrogen atom, while by the aryl groups mentioned in the definition of the above groups is meant in each case a phenyl group which is mono- or disubstituted by R6, 25 while the substituents may be identical or different and R denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom or a Ci-3-aikyi, hydroxy, Ci-3-alkyloxy, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy or cyano group, 30 by the heteroaryl groups mentioned in the definition of the above groups is meant a pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl group, while the above-mentioned heteroaryl groups are mono- or disubstituted in each case by the 4 6 6 group R , while the substituents may be identical or different and R is as hereinbefore defined, and unless otherwise stated, the above-mentioned alkyl groups may be straight-5 chain or branched. Preferred compounds of the above general formula I are those wherein Ra denotes a hydrogen atom, 10 b 13 R denotes a phenyl group substituted by the groups R to R , while R1 denotes a hydrogen, fluorine, chlorine or bromine atom, 15 a methyl, trifluoromethyl or ethynyl group, a phenyloxy or phenylmethoxy group, while the phenyl moiety of the above-mentioned groups is optionally substituted by a fluorine or chlorine atom, or 20 a pyridinyloxy or pyridinylmethoxy group, while the pyridinyl moiety of the above-mentioned groups is optionally substituted by a methyl or trifluoromethyl group, 25 R2 denotes a hydrogen, fluorine or chlorine atom and R3 denotes a hydrogen atom, Rc denotes a hydrogen atom, 30 a Ci-3-alkyloxy group, a C4-6-cycloalkyloxy or C3-6-cycloalkyl-Ci-2-alkyloxy group, 5 a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranyl-Ci-2-alkyloxy or tetrahydropyranyl-C-i-2-alkyIoxy group, an ethyloxy group which is substituted in the 2 position by a group R4, where 5 R4 denotes a hydroxy, C-t-3-alkyloxy, amino, Ci-3-alkylamino, di-(Ci-3-alkyl)amino, bis-(2-methoxyethyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, homopiperidin-1-yl, morpholin-4-yl, homomorpholin-4-yl, piperazin-1-yl, 4-(Ci-3-alkyl)-piperazin-1-yl, homopiperazin-1-yl or 4-(Ci-3-alkyl)-10 homopiperazin-1-yl group, a propyloxy group which is substituted by a group R4 in the 3 position, while R4 is as hereinbefore defined, or 15 a butyloxy group which is substituted by a group R4 in the 4 position, while R4 is as hereinbefore defined, Re and Rd, which may be identical or different, in each case denote a hydrogen atom or a methyl group 20 and X denotes a nitrogen atom, 25 while, unless otherwise stated, the above-mentioned alkyl groups may be straight-chain or branched, the tautomers, their stereoisomers, the mixtures thereof and the salts thereof. 30 Particularly preferred compounds of the above general formula I are those wherein Ra denotes a hydrogen atom, 6 Rb denotes a 3-ethynylphenyl, 3-bromophenyl, 3,4-difluorophenyl or 3-chloro-4-fluoro-phenyl group, Rc denotes a hydrogen atom, 5 a methoxy, ethyloxy, 2-(methoxy)ethyloxy, 3-(morpholin-4-yl)propyloxy, cyclo-butyloxy, cyclopentyloxy, cyclohexyloxy, cyclopropylmethoxy, cyclopentylmethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-10 ylmethoxy or tetrahydropyran-4-ylmethoxy group, Re and Rd in each case denote a hydrogen atom and 15 X denotes a nitrogen atom, the tautomers, their stereoisomers, the mixtures thereof and the salts thereof. 20 Most particularly preferred compounds of general formula f are those wherein Ra denotes a hydrogen atom, Rb denotes a 3-chloro-4-fluoro-phenyl group, 25 Rc denotes a tetrahydrofuran-3-yloxy group, Re and Rd in each case denote a hydrogen atom 30 and X denotes a nitrogen atom, the tautomers, their stereoisomers, the mixtures thereof and the salts thereof. 7 The following particularly preferred compound of general formula I is mentioned by way of example: 5 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline and the salts thereof. 10 The compounds of general formula I may be prepared by the following methods, for example: a) reacting a compound of general formula ^Rb O N 15 , (II) wherein Ra, Rb, Rc and X are as hereinbefore defined and R7 and R8, which may be identical or different, denote Ci-4-alkyl groups, with a compound of general 20 formula R- . (Ml) wherein 25 Rd and Re are as hereinbefore defined. 8 The reaction is expediently carried out in a solvent or mixture of solvents such as tetrahydrofuran, tetrahydrofuran/water, acetonitrile, acetonitrile/water, dioxane, ethyleneglycol dimethyl ether, isopropanol, methylene chloride, 5 dimethylformamide or sulpholane, optionally in the presence of an inorganic or organic base, e.g. sodium carbonate, potassium hydroxide or 1,8-diazabicyclo[5.4.0]undec-7-ene and optionally in the presence of a lithium salt such as lithium chloride at temperatures between -50 and 150°C, but preferably at temperatures between -20 and 80°C. The reaction may also be 10 carried out with a reactive derivative of the compound of general formula III, for example the hydrate or a hemiacetal. b) reacting a compound of general formula wherein Ra, Rb, Rc and X are as hereinbefore defined and Z1 denotes a leaving group such as a halogen atom or a substituted sulphonyloxy group such as a chlorine or bromine atom, a methanesulphonyloxy or p-toiuenesulphonyloxy 20 group, with a compound of general formula 15 R' ,<V) wherein Rd and Re are as hereinbefore defined. 25 9 The reaction is expediently carried out in a solvent such as isopropanol, butanol, tetrahydrofuran, dioxane, acetonitrile, dimethylformamide, sulpholane, toluene or methylene chloride or mixtures thereof, optionally in the presence of an inorganic or organic base, e.g. sodium carbonate, 5 potassium carbonate, potassium hydroxide, triethylamine or N-ethyl- diisopropylamine and optionally in the presence of a reaction accelerator such as an alkali metal iodide at temperatures between -20 and 150°C, but preferably at temperatures between 0 and 100°C. The reaction may however also be carried out without a solvent or in an excess of the compound of 10 general formula V used. In the reactions described hereinbefore, any reactive groups present such as hydroxy, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the 15 reaction. For example, a protecting group for a hydroxy group may be a trimethylsilyl, acetyl, trityl, benzyl or tetrahydropyranyl group. 20 Protecting groups for an amino, alkylamino or imino group may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group. Any protecting group used is optionally subsequently cleaved for example by 25 hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at 30 temperatures between 0 and 120°C, preferably at temperatures between 10 and 100°C. However, a benzyl, methoxybenzyi or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst 10 such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100°C, but preferably at temperatures between 20 and 60°C, and at a hydrogen pressure of 1 to 7 bar, 5 but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisol. A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with 10 iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxane, methanol or diethylether. A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at 15 temperatures between 50 and 120°C or by treating with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50°C. Moreover, the compounds of general formula I obtained may be resolved into 20 their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers. 25 Thus, for example, the cis/trans mixtures may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in 'Topics in Stereochemistry", Vol. 6, Wiley interscience, 1971) into their optical antipodes and compounds of general 30 formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known perse, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above. 11 The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the 5 activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric 10 acid or dibenzoyltartaric acid, di-Q-p-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (-)-menthyloxycarbonyl. 15 Furthermore, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, 20 sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid. As already mentioned hereinbefore, the compounds of general formula I according to the invention and the physiologically acceptable salts thereof 25 have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by the Epidermal Growth Factor receptor (EGF-R), whilst this may be achieved for example by inhibiting ligand bonding, receptor dimerisation or tyrosinekinase itself. It is also possible to block the transmission of signals to components located further downstream. 30 The biological properties of the new compounds were investigated as follows: The inhibition of human EGF-receptor kinase was determined using the cytoplasmatic tyrosine kinase domain (methionine 664 to alanine 1186, based 12 on the sequence published in Nature 309 (1984), 418). To do this, the protein was expressed in Sf9 insect cells as a GST fusion protein using the Baculovirus expression system. 5 The enzyme activity was measured in the presence or absence of the test compounds in serial dilutions. The polymer pEY (4:1) produced by SIGMA was used as the substrate. Biotinylated pEY (bio-pEY) was added as the tracer substrate. Every 100 pi of reaction solution contained 10 fjl of the inhibitor in 50% DMSO, 20 pi of the substrate solution (200 mM HEPES pH 10 7.4, 50 mM magnesium acetate, 2.5 mg/ml of poly(EY), 5 pg/ml of bio-pEY) and 20 pi of enzyme preparation. The enzyme reaction was started by the addition of 50pl of a 100pM ATP solution in 10 mM magnesium chloride. The dilution of the enzyme preparation was adjusted so that the incorporation of phosphate into the bio-pEY was linear in terms of time and quantity of 15 enzyme. The enzyme preparation was diluted in 20 mM HEPES pH 7.4, 1 mM EDTA, 130 mM common salt, 0.05% Triton X-100,1 mM DTT and 10% glycerol. The enzyme assays were carried out at ambient temperature over a period of 30 minutes and were ended by the addition of 50 pi of a stopping solution (250 mM EDTA in 20 mM HEPES pH 7.4). 100 pi were placed on a streptavidin-coated microtitre plate and incubated for 60 minutes at ambient temperature. Then the plate was washed with 200 pi of a washing solution (50 mM Tris, 0.05% Tween 20). After the addition of 100 pi of a HRPO-labelled anti-PY antibody (PY20H Anti-PTyr:HRP produced by Transduction Laboratories, 250 ng/ml) it was incubated for 60 minutes. Then the microtitre plate was washed three times with 200 pi of washing solution. The samples were then combined with 100 pi of a TMB-peroxidase solution (A:B = 1:1, Kirkegaard Perry Laboratories). After 10 minutes the reaction was stopped. The extinction was measured at OD450nm with an ELISA reader. All data points were measured three times. The data were matched using an iterative calculation using an analytical programme for sigmoidal curves (Graph Pad Prism Version 3.0; sigmoid 20 25 30 13 curves, variable pitch). All the iteration data released showed a correlation coefficient of more than 0.9. The maxima and minima of the curves showed a spread of at least a factor of 5. The ICso (concentration of active substance which inhibits the activity of EGF-receptor kinase by 50%) was determined 5 from the curves. The following results were obtained: Compound (Example No.) Inhibition of EGF-receptor kinase IC50 EnM] 1 1.5 10 The compounds of general formula I according to the invention thus inhibit signal transduction by tyrosine kinases, as demonstrated by the example of the human EGF receptor, and are therefore useful for treating pathophysiological processes caused by hyperfunction of tyrosine kinases. These are e.g. benign or malignant tumours, particularly tumours of epithelial 15 and neuroepithelial origin, metastasisation and the abnormal proliferation of vascular endothelial cells (neoangiogenesis). The compounds according to the invention are also useful for preventing and treating diseases of the airways and lungs which are accompanied by 20 increased or altered production of mucus caused by stimulation by tyrosine kinases, e.g. in inflammatory diseases of the airways such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, a1-antitrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive 25 airways. The compounds are also suitable for treating diseases of the gastrointestinal tract and bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in chronic 14 inflammatory changes such as cholecystitis, Crohn's disease, ulcerative colitis, and ulcers in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated with increased secretions, such as Menetrier's disease, secreting adenomas and protein loss 5 syndrome. In addition, the compounds of general formula I and the physiologically acceptable salts thereof may be used to treat other diseases caused by abnormal function of tyrosine kinases, such as e.g. epidermal 10 hyperproliferation (psoriasis), benign prostatic hyperplasia (BPH), inflammatory processes, diseases of the immune system, hyperproliferation of haematopoietic cells, treatment of nasal polyps, etc. By reason of their biological properties the compounds according to the 15 invention may be used on their own or in conjunction with other pharmacologically active compounds, for example in tumour therapy, in monotherapy or in conjunction with other anti-tumour therapeutic agents, for example in combination with topoisomerase inhibitors (e.g. etoposide), mitosis inhibitors (e.g. vinblastine), compounds which interact with nucleic acids (e.g. 20 cis-platin, cyclophosphamide, adriamycin), hormone antagonists (e.g. tamoxifen), inhibitors of metabolic processes (e.g. 5-FU etc.), cytokines (e.g. interferons), antibodies, etc. For treating respiratory tract diseases, these compounds may be used on their own or in conjunction with other therapeutic agents for the airways, such as substances with a secretolytic (e.g. ambroxol, 25 N-acetylcysteine), bronchoiytic (e.g. tiotropium or ipratropium or fenoterol, salmeterol, salbutamol) and/or anti-inflammatory activity (e.g. theophylline or glucocorticoids). For treating diseases in the region of the gastrointestinal tract, these compounds may also be administered on their own or in conjunction with substances having an effect on motility or secretion. These 30 combinations may be administered either simultaneously or sequentially. These compounds may be administered either on their own or in conjunction with other active substances by intravenous, subcutaneous, intramuscular, 15 intraperitoneal or intranasal route, by inhalation or transdermal or orally, whilst aerosol formulations are particularly suitable for inhalation. For pharmaceutical use the compounds according to the invention are 5 generally used for warm-blooded vertebrates, particularly humans, in doses of 0.01-100 mg/kg of body weight, preferably 0.1-15 mg/kg. For administration they are formulated with one or more conventional inert carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, 10 water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof in conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories. 15 The following Examples are intended to illustrate the present invention without restricting it: 16 Prepa ration of the starting compou nds: Example I 4-f(3-chloro-4-fluoro-phenvl)amino1-6-f(diethoxy-phosphorvl')-acetvlaminol-7-5 f(S)-ftetrahvdrofurari-3-vl)oxv1-quinazoline 60.07 g of diethoxyphosphorylacetic acid are placed in 750 ml of N,N-dimethylformamide and at ambient temperature combined with 48.67 g of N.N'-carbonyldiimidazoie. After the development of gas has ceased 90.00 g of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-amino-[(S)-(tetrahydrofuran-3-yl)oxy]-10 quinazoline are added and the reaction mixture is stirred for about 4-5 hours at ambient temperature until the reaction is complete. The reaction mixture is then heated gently in the water bath and 750 ml of water are added twice. The thick suspension is stirred overnight and the next morning another 350 ml of water are added. The suspension is cooled in the ice bath, stirred for one hour 15 and suction filtered. The filter cake is washed again with 240 ml of N,N-dimethylformamide/water (1:2) and 240 ml of diisopropylether and dried at 40°C in the circulating air dryer. Yield: 117.30 g of (88 % of theory) Rf value: 0.37 (silica gel, methylene chloride/methanol = 9:1) 20 Mass spectrum (ESf): m/z = 553, 555 [M+H]+ The following compounds are obtained analogously to Example I: (1) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(diethoxy-phosphoryl)-acetylamino]-25 7-[(/?)-(tetrahydrofuran-3-yl)oxy]-quinazoline Mass spectrum (ESI+): m/z = 553, 555 [M+H]+ (2) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(diethoxy-phosphoryl)-acetylamino]-7-cyclopropylmethoxy-quinazoline 30 melting point: 185-187°C (3) 4-[(3-bromophenyl)amino]-6-[(diethoxy-phosphoryl)-acetylamino]-quinazoline Mass spectrum (ESf): m/z = 491, 493 [M-H]~ 17 (4) 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(diethoxy-phosphoryl)-acetylamino]-7-cyclopentyloxy-quinazoline Rf value: 0.54 (silica gel, methylene chloride/ethanol = 20:1) 5 Example II Homomorpholin-4-vl-acetaldehyde-hvdrochloride Prepared by stirring (2.5 hours) 4-(2,2-dimethoxy-ethyl)-homomorpholine with semiconcentrated hydrochloric acid at 80°C. The solution obtained is further 10 reacted directly as in Example 1. Example III 4-(2.2-dimethoxv-ethvl)-homomorpholine Prepared by stirring (5 hours) homomorpholine-hydrochloride with 15 bromoacetaldehyde-dimethylacetal in the presence of potassium carbonate in N-methylpyrrolidinone at 80°C. Rf value: 0.2 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia = 90:10:1) 20 18 Preparation of the final compounds: Example 1 4-f(3-chloro-4-fluoro-phenv0amino1-6-(r4-(homomorpholin-4-vlH-oxo-2-buten-5 1-vnamino)-7-r(S)-(tetrahvdrofuran-3-vltoxvl-quinazoline A solution of 3.9 g of 4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(diethoxy-10 phosphoryl)-acetylamino]-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline in 20 ml of tetrahydrofuran is added to a solution of 300 mg of lithium chloride in 20 ml of water at ambient temperature. Then 2.35 g of potassium hydroxide flakes are added and the reaction mixture is cooled to -3°C in an ice/acetone cooling bath. The solution of the homomorpholin-4-yl-acetaldehyde hydro-15 chloride obtained in Example II is then added dropwise within 5 min at a temperature of 0°C. After the addition has ended the reaction mixture is stirred for another 10 min at 0°C and for a further hour at ambient temperature. For working up 100 ml of ethyl acetate are added and the aqueous phase is separated off. The organic phase is washed with saturated 20 sodium chloride solution, dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column using ethyl acetate/methanol/conc. methanolic ammonia as eluant. The product obtained is stirred with a little diisopropyl ether, suction filtered and dried. 25 Yield: 2.40 g of (63 % of theory) Rf value: 0.09 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia = 90:10:1) Mass spectrum (ESI+): m/z = 542, 544 [M+H]+ F O 19 The following compounds may also be prepared analogously to the foregoing Examples and other methods known from the literature: Example No. Structure (1) N^V^Vnh /0 (2) I (3) n-L^Vnh W5 k (4) YX c,AiANH °Y^^n-^\ n-L/v™ U° s 0^ 20 Example No. Structure (5) 'XI cr NH Y N \ vXA0 ^■N^I o° (6) 0 $ "" o (7) C,XXNH °y~^N^ N-Wm ^-/° i (8) CIXXNH n-V^NH I^J> vXA0 6 21 Example No. Structure (9) CIXXNH V (10) eXX« °Y^N-^ N-k/wNH 1^° VXA So (11) ci^^-r^NH 0Y^ N^"~A /L^.nh C p N x—J (12) 'XI 0^.^ cr NH N \ NVy"1 tV-^° 6 22 Example No. Structure (13) 'XI cr NH N \ N-Vv™ 6 (14) n-Vvh U° So (15) FXI <V— ^ CT^TJH y N \ »VrNH vXA0 L"oO (16) c,XXNH n-V^NH O0 vIA, v> ^0 23 Example No. Structure (17) 'XX 1^.NH C P KXJL N^O "o (18) n\^nh vW0 0 (19) FXXH ,-L^nh U° 6 (20) CIXXNH 1^.NH C P N x ' i JLi 6 24 Example No. Structure (21) XX Br NH y N \ n-V-vnh U3 vXA 6 Example 2 Coated tablets containing 75 mg of active substance 5 1 tablet core contains: active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg 10 polyvinylpyrrolidone 10.0 mg hydroxypropyimethylcellulose 15.0 mg magnesium stearate 1.5 mg 230.0 mg 15 Preparation: The active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropyimethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-20 making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate. This granulate is compressed in a tablet-making machine to form tablets of the desired shape. Weight of core: 230 mg 25 die: 9 mm, convex 25 The tablet cores thus produced are coated with a film consisting essentially of hydroxypropyimethylcellulose. The finished film-coated tablets are polished with beeswax. Weight of coated tablet: 245 mg. 5 Example 3 Tablets containing 100 mg of active substance 10 Composition: 1 tablet contains: active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mg 220.0 mg Method of Preparation: 20 The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50°C it is screened again (1.5 mm mesh size) and the lubricant is 25 added. The finished mixture is compressed to form tablets. Weight of tablet: 220 mg Diameter: 10 mm, biplanar, facetted on both sides and notched on one side. 30 26 Example 4 Tablets containing 150 mg of active substance 5 Composition: 1 tablet contains: active substance powdered lactose corn starch 150.0 mg 89.0 mg 40.0 mg 10.0 mg 10.0 mg 1-0 mg 300.0 mg 10 colloidal silica polyvinylpyrrolidone magnesium stearate 15 Preparation: The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45°C, are passed 20 through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture. Weight of tablet: 300 mg die: 10 mm, flat 25 Example 5 Hard gelatine capsules containing 150 mg of active substance 1 capsule contains: 30 active substance 150.0 mg approx. 180.0 mg approx. 87.0 mg 3.0 mg corn starch (dried) lactose (powdered) magnesium stearate approx. 420.0 mg 27 Preparation: The active substance is mixed with the excipients, passed through a screen 5 with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules. Capsule filling: approx. 320 mg Capsule shell: size 1 hard gelatine capsule. 10 Example 6 Suppositories containing 150 mg of active substance 15 1 suppository contains: active substance 150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg 20 2,000.0 mg Preparation: After the suppository mass has been melted the active substance is 25 homogeneously distributed therein and the melt is poured into chilled moulds. 28 Example 7 Suspension containing 50 mg of active substance 5 100 ml of suspension contain: active substance 1.00 g carboxymethylceliulose-Na-salt 0.10 g methyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g 10 glucose 10.00g glycerol 5.00 g 70% sorbitol solution 20.00 g flavouring 0.30 g dist. water ad 100 ml 15 Preparation: The distilled water is heated to 70°C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of 20 carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air. 25 5 ml of suspension contain 50 mg of active substance. Example 8 Ampoules containing 10 mg active substance 30 Composition: active substance 10.0 mg 0.01 N hydrochloric acid q.s. double-distilled water ad 2.0 ml 29 Preparation: The active substance is dissolved in the requisite amount of 0.01 N HCI, made 5 isotonic with common salt, filtered sterile and transferred into 2 ml ampoules. Example 9 Ampoules containing 50 mg of active substance 10 Composition: active substance 50.0 mg 0.01 N hydrochloric acid q.s. double-distilled water ad 10.0 ml 15 Preparation: The active substance is dissolved in the necessary amount of 0.01 N HCI, 20 made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules. Example 10 25 Capsules for powder inhalation containing 5 mg of active substance 1 capsule contains: 30 active substance 5.0 mg lactose for inhalation 15.0 mg 20.0 mg </div>

Claims

<div class="application article clearfix printTableText" id="claims"> 30 Preparation: The active substance is mixed with lactose for inhalation. The mixture is packed into capsules in a capsule-making machine (weight of the empty capsule approx. 50 mg). 5 weight of capsule: 70.0 mg size of capsule 3 Example 11 10 Solution for inhalation for hand-held nebulisers containing 2.5 mg active substance 1 spray contains: 15 active substance 2.500 mg benzalkonium chloride 0.001 mg 1N hydrochloric acid q.s. ethanol/water (50/50) ad 15.000 mg 20 Preparation: The active substance and benzalkonium chloride are dissolved in ethanol/water (50/50). The pH of the solution is adjusted with 1N hydrochloric acid. The resulting solution is filtered and transferred into suitable containers 25 for use in hand-held nebulisers (cartridges). Contents of the container: 4.5 g 31 Patent Claims

1. Bicyclic heterocycles of general formula Ra denotes a hydrogen atom or a Ci-*-alkyl group, 10 Rb denotes a phenyl, benzyl or 1-phenylethyl group, wherein the phenyl 1 3 nucleus in each case is substituted by the groups R to R , while R1 and R2, which may be identical or different, in each case denote a hydrogen, fluorine, chlorine, bromine or iodine atom, 15 a Ci-4-alkyl, hydroxy, Ci-4-alkoxy, C2-3-alkenyl or C2-3-alkynyl group, an aryl, aryloxy, arylmethyl or aryl methoxy group, 20 a heteroaryl, heteroaryloxy, heteroarylmethyl or heteroarylmethoxy group, a methyl or methoxy group substituted by 1 to 3 fluorine atoms or 25 a cyano, nitro or amino group, and R3 denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl or trifluoromethyl group, 32 Rc denotes a hydrogen atom or a fluorine, chlorine or bromine atom, a hydroxy or Ci-4-alkyloxy group, 5 a methoxy group substituted by 1 to 3 fluorine atoms, an ethyloxy group substituted by 1 to 5 fluorine atoms, 10 a C2-4-alkyloxy group which is substituted by a group R4, while R4 denotes a hydroxy, Ci-3-alkyloxy, C3-6-cycloalkyloxy, C3-6-cycloalkyl-Ci-3-alkyloxy, amino, Ci-3-alkylamino, di-(Ci-3-alkyl)amino, bis-(2-Ci-3-alkyloxy-ethyl)-amino, bis-(3-Ci-3-alkyloxy-propyl)-amino, pyrrolidin-1 -yl, 15 piperidin-1-yl, homopiperidin-1-yl, morpholin-4-yl, homomorpholin-4-yl, piperazin-1-yl, 4-(Ci-3-alkyl)-piperazin-1-yl, homopiperazin-1-yl or4-(Ci-3-alkyl)-homopiperazin-1-yl group, a C3-7-cycloalkyloxy or C3-7-cycloalkyl-Ci-4-alkyloxy group, 20 a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy or tetrahydropyran-4-yloxy group, a tetrahydrofuranyl-Ci-4-alkyloxy or tetrahydropyranyl-Ci-4-alkyloxy group, 25 a pyrrolidin-3-yloxy, piperidin-3-y!oxy or piperidin-4-yloxy group, a 1-(Ci-3-alkyl)-pyrrolidin-3-yloxy, 1-(Ci-3-alkyl)-piperidin-3-yloxy or 1-(Ci-3-alkyl>piperidin-4-yloxy group, 30 a Ci-4-alkoxy group which is substituted by a pyrrolidinyl, piperidinyl or homopiperidinyl group substituted in the 1 position by the group R5, where R5 denotes a hydrogen atom or a Ct-3-alkyl group, 33 or a Ci-4-alkoxy group which is substituted by a morpholinyl or homomorpholinyl group substituted in the 4 position by the group R5, where R5 is as hereinbefore defined, 5 Re and Rd, which may be identical or different, in each case denote a hydrogen atom or a C-i-3-alkyl group and 10 X denotes a methyne group substituted by a cyano group or a nitrogen atom, while by the aryl groups mentioned in the definition of the above groups is g meant in each case a phenyl group which is mono- or disubstituted by R , 15 while the substituents may be identical or different and R denotes a hydrogen atom, a fluorine, chlorine, bromine or iodine atom or a Ci-3-alkyl, hydroxy, Ci-3-alkyloxy, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy or cyano group, 20 by the heteroaryl groups mentioned in the definition of the above groups is meant a pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl group, while the above-mentioned heteroaryl groups are mono- or disubstituted in each case by the group R6, while the substituents may be identical or different and R6 is as 25 hereinbefore defined, and unless otherwise stated, the above-mentioned alkyl groups may be straight-chain or branched, 30 the tautomers, their stereoisomers, the mixtures thereof and the salts thereof. 34

2. Bicyclic heterocycles of general formula I according to claim 1, wherein Ra denotes a hydrogen atom, b 13 5 R denotes a phenyl group substituted by the groups R to R , while R1 denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl, trifluoromethyl or ethynyl group, 10 a phenyloxy or phenylmethoxy group, while the phenyl moiety of the above-mentioned groups is optionally substituted by a fluorine or chlorine atom, or 15 a pyridinyloxy or pyridinylmethoxy group, while the pyridinyl moiety of the above-mentioned groups is optionally substituted by a methyl or trifluoromethyl group, R2 denotes a hydrogen, fluorine or chlorine atom and 20 R3 denotes a hydrogen atom, R° denotes a hydrogen atom, 25 a Ci-3-alkyioxy group, a C4-6-cycloalkyloxy or C3-6-cycloalkyl-Ci~2-alkyloxy group, a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, 30 tetrahydrofuranyl-C-i-2-aJkyloxy or tetrahydropyranyl-Ci-2-alkyloxy group, an ethyloxy group which is substituted in the 2 position by a group R4, where 35 R4 denotes a hydroxy, Ci-3-aIkyloxy, amino, Ci-3-aikylamino, di-(Ci-3-alkyl)amino, bis-(2-methoxyethyl)-amino, pyrrolidin-1-yl, piperidin-1 -yl, homopiperidin-1-yl, morpholin-4-yl, homomorpholin-4-yl, piperazin-1-yl, 4-{Ci-3-a!kyl)-piperazin-1-yl, homopiperazin-1-yl or4-(Ci-3-alkyl)-5 homopiperazin-1 -yl group, a propyloxy group which is substituted by a group R4 in the 3 position, while R4 is as hereinbefore defined, or 4 4 10 a butyloxy group which is substituted by a group R in the 4 position, while R is as hereinbefore defined, Re and Rd, which may be identical or different, in each case denote a hydrogen atom or a methyl group 15 • and X denotes a nitrogen atom, 20 while, unless otherwise stated, the above-mentioned alkyl groups may be straight-chain or branched, the tautomers, their stereoisomers, the mixtures thereof and the salts thereof. 25

3. Bicyclic heterocycles of general formula I according to claim 1, wherein Ra denotes a hydrogen atom, Rb denotes a 3-ethynylphenyl, 3-bromophenyl, 3,4-difluorophenyi or3-chloro-30 4-fluoro-phenyl group, Rc denotes a hydrogen atom, 36 a methoxy, ethyloxy, 2-(methoxy)ethyloxy, 3-(morpholin-4-yl)propyloxy, cyclo-butyloxy, cyclopentyloxy, cyclohexyloxy, cyclopropylmethoxy, cyclopentylmethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-5 ylmethoxy or tetrahydropyran-4-ylmethoxy group, 6 d R and R in each case denote a hydrogen atom and 10 X denotes a nitrogen atom, the tautomers, their stereoisomers, the mixtures thereof and the salts thereof. 15

4. Bicyclic heterocycles of general formula I according to claim 1, wherein Ra denotes a hydrogen atom, 20 Rb denotes a 3-chloro-4-fluoro-phenyl group, Rc denotes a tetrahydrofuran-3-yloxy group, Re and Rd in each case denote a hydrogen atom 25 and X denotes a nitrogen atom, 30 the tautomers, their stereoisomers, the mixtures thereof and the salts thereof. 37

5. The following compound of general formula I according to claim 1: 4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-{tetrahydrofuran-3-yl)oxy]-quinazoiine 5 and the salts thereof.

6. Physiologically acceptable salts of the compounds according to at least one 10 of claims 1 to 5 with inorganic or organic acids or bases.

7. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 5 or a physiologically acceptable salt according to claim 6, 15 optionally together with one or more inert carriers and/or diluents.

8. Use of a compound according to at least one of claims 1 to 6 for preparing a pharmaceutical composition for the treatment of benign or malignant 20 tumours, for the prevention and treatment of diseases of the airways and lungs, for the treatment of diseases of the gastro-intestinal tract or bile duct and gall bladder. 25

9. Process for preparing a pharmaceutical composition according to claim 7, characterised in that a compound according to at least one of claims 1 to 6 is incorporated in one or more inert carriers and/or diluents by a non-chemical method. 30 38

10. Process for preparing the compounds of general formula I according to claims 1 to 6, characterised in that a) a compound of general formula 5 wherein Ra, Rb, Rc and X are defined as in claims 1 to 5 and R7 and R8, which may be 10 identical or different, denote Ci-4-alkyl groups, is reacted with a compound of general formula Rd R° . on) 15 wherein Rd and Re are defined as in claims 1 to 5, or b) a compound of general formula 20 39 5* 2*0-2 wherein Ra, Rb, Rc and X are defined as in claims 1 to 5 and Z1 denotes a leaving group, is reacted with a compound of general formula Rd wherein Rd and Re are defined as in claims 1 to 5, and if necessary any protecting group used in the reactions described above is 10 cleaved again and/or if desired a compound of general formula I thus obtained is resolved into the stereoisomers thereof and/or 15 a compound of general formula I thus obtained is converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof. </div>